Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

NATerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
ThalassemiaSickle Cell DiseaseGlanzmann ThrombastheniaWiskott-Aldrich SyndromeChronic-granulomatous DiseaseSevere Congenital NeutropeniaLeukocyte Adhesion DeficiencySchwachman-Diamond SyndromeDiamond-Blackfan AnemiaFanconi AnemiaDyskeratosis-congenitaChediak-Higashi SyndromeSevere Aplastic Anemia
Interventions
DRUG

Alefacept

0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.

Trial Locations (1)

30322

Children's Healthcare of Atlanta, Atlanta

Sponsors
All Listed Sponsors
collaborator

Children's Healthcare of Atlanta

OTHER

lead

Emory University

OTHER

NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter